AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02424539 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo as a aqueous suspension to match the other study treatments minus the active component(s) for intranasal inhalation administered via a metered side-actuated nasal spray device.
Study NCT00337636 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery to implant human CNS stem cells (HuCNS-SC)
Description: single dose
Study NCT00337636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medication to suppress the immune system
Description: Immunosuppression for 12 months post transplant
Study NCT03500107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue Light Emitting Diode (LED) 401 +/- 5nm
Description: The participant will be naked, in a gynecological stretcher and lithotomy position, and the apparatus of the LED will be positioned in front of the vulva and vaginal region, 5 cm away, it will be statically, externally, and supported on a tripod. The protocol will consist of only one session.
Study NCT01821677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol Capsules
Study NCT01821677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00085969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.04 mL twice daily
Description: Subcutaneously injected, 0.04 mL, twice daily
Study NCT00085969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.04 mL once daily
Description: Subcutaneously injected, 0.04 mL, once daily
Study NCT03442465 — intervention group
Intervention type: BEHAVIORAL
Intervention: Toronto Extremity Salvage Score
Description: Participant-reported outcome score. For lower extremities, this is a 33 item questionnaire containing 32 5 point Likert scale items and 1 open ended response item. For upper extremities, this is a 31 item questionnaire containing 31 5 point Likert scale items and 1 open ended response item. Individual item responses range from 1-5 with higher values indicating a task is easier to complete. A total questionnaire score can also be calculated by taking the sum of the scores minus the number of total items answered, and dividing this by the maximum possible score based on the number of items answered. This results in a range from 0 -100% with higher values indicating greater ability to complete tasks 31. This scoring allows for the fact that some items may not be answered if they do not apply to an individual. It is anticipated that it will take 20 minutes to complete. Scores for the lower extremity and upper extremity may be combined, but we intend to treat them separately for analysis.
Study NCT02606747 — intervention group
Intervention type: OTHER
Description: routine blood sugar control
Study NCT03442465 — intervention group
Intervention type: BEHAVIORAL
Intervention: Musculoskeletal Tumor Society Score
Description: Clinician-reported global score. For lower extremities, this is a 6 item questionnaire containing 6 point Likert scale items which cover pain, function, emotional acceptance, walking ability, gait, and necessary support. Individual item scores range from 0-5 with higher values indicating greater function, less pain, or more positive emotional acceptance. For upper extremities, this is a 6 item questionnaire containing 6 point Likert scale items which cover pain, function, emotional acceptance, hand positioning, manual dexterity, and lifting ability. Individual item scores range from 0-5 with higher values indicating greater function, less pain, or more positive emotional acceptance. A total questionnaire score which is defined as the sum of the individual items divided by the maximum possible score (5 times the number of items) may also be computed. It is represented as a percentage from 0 - 100%.
Study NCT03442465 — intervention group
Intervention type: BEHAVIORAL
Intervention: Timed Get Up and Go Test
Description: Validated functional measurement, for lower extremities only. The patient is observed and timed while s/he rises from an arm chair, walks 3 meters, turns, walks back, and sits down again. The test predicts the patient's ability to go outside alone safely and quantifies functional mobility. The test requires no special equipment and will take less than one minute to complete.
Study NCT00085969 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.08 mL once daily
Description: Subcutaneously injected, 0.08 mL, once daily
Study NCT00085969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B - Exenatide 10 mcg twice daily
Description: Subcutaneously injected, 10 mcg (0.04 mL), twice daily
Study NCT03442465 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Orthogonal Radiographs
Description: The distance of bone transport is measured, accounting for calibration of the radiographs. The presence of bone regenerate between the transported segment is determined by the presence of continuous calcified callus from the proximal segment to the distal segment. Each of the orthogonal radiographs is used to visualize two cortices: the AP radiographs visualizes the medial and lateral cortices and the lateral radiograph measures the anterior and posterior cortices. Each continuous calcified cortex is counted with a range from 0 to 4 cortices intact.
Study NCT03442465 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Weight Bearing for lower extremities only
Description: As part of the current standard of care, patients are asked to stand on a scale with the affected lower extremity on the scale and the unaffected extremity on a block which is level with the scale. The patient is asked to place as much weight as possible on the affected extremity and this weight Is recorded. Each patient's total weight is then measured and the percent of weight bearing is calculated as the amount of weight bearing over the total body weight.
Study NCT03442465 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Range of Motion
Description: As part of the current standard of care, the joints of the affected extremity are assessed for passive range of motion at each follow up visit by the clinician. If surgery is on the femur, the hip and knee joints are assessed for range of motion. Whereas for the tibia, the knee and ankle joints are assessed. These assessments would be measured using a goniometer placed alongside the extremity and recorded for each direction of movement. Hip range of motion includes flexion, extension, abduction, internal rotation and external rotation. Knee range of motion includes flexion and extension. Ankle range of motion includes dorsiflexion and plantarflexion.
Study NCT04460794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ballet-inspired workouts
Description: 8 weeks, delivered by volunteers with a self-directed resource package
Study NCT04460794 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care and general recommendations on basic stretching and leg exercises for stroke survivors
Study NCT02213107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide and Dutasteride or finasteride
Description: Use of either two oral drugs together~1. Enzalutamide by mouth daily and dutasteride by mouth daily or~2. Enzalutamide by mouth daily and finasteride by mouth daily
Study NCT04517799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiolex
Description: While in the intervention arm subjects will receive EPIDIOLEX, an oral purified CBD solution developed by GW Pharmaceuticals. The formulation is a 100 mg/mL solution, which allows for easy dose titration and administration even to young children. EPIDIOLEX is naturally-derived CBD, and has been found to have a purity of over 98%. The solution includes a sweetener to make it palatable. Dosing is dependent upon each subject's weight.~The dosage will be titrated over time as follows:~Week 1: 5 mg/kg/day, divided into 2 doses Week 2: 10 mg/kg/day, divided into 2 doses Weeks 3-8: 20 mg/kg/day, divided into 2 doses If a child's weight changes by greater than 2 kg during the study, the dose will be adjusted to reflect the weight change.
Study NCT04517799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo oral solution
Description: GW has developed a placebo that is identical in color and taste, and will be administered in the same volume as the CBD, so that parents and investigators should not be able to detect differences between the 2 treatments. Dosing is dependent upon each subject's weight.~The dosage will be titrated as follows:~Week 1: 5 mg/kg/day, divided into 2 doses Week 2: 10 mg/kg/day, divided into 2 doses Weeks 3-8: 20 mg/kg/day, divided into 2 doses If a child's weight changes by greater than 2 kg during the study, the dose will be adjusted to reflect the weight change.
Study NCT03847090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reloxaliase
Description: Reloxaliase 2 capsules, orally, with each meal/snack, 3 to 5 times per day
Study NCT03847090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day
Study NCT00609973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Ciprofloxacin 500 mg oral bid for 6 months
Study NCT00609973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo bid for 6 months
Study NCT02216851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Perlane
Description: Intradermal injection
Study NCT03242733 — intervention group
Intervention type: OTHER
Intervention: Ultrasound assessment of gastric contents
Description: Ultrasound assessment of gastric contents is performed in fasted elderly patients for hip fracture surgery.
Study NCT03399123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tidal volume
Description: After General anesthesia, patients that during volume control mode of mechanical ventilation in experimental group, we take low tidal volume.
Study NCT03399123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tidal volume
Description: After General anesthesia, patients that during volume control mode of mechanical ventilation in experimental group, we take low tidal volume.
Study NCT02106559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: porfimer sodium
Description: Given IV
Study NCT02106559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo tumor resection and/or radical pleurectomy
Study NCT02106559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: Undergo PDT
Study NCT03309059 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: water and soap
Description: Use of soap and water in the area and subsequent diaper placement disposable.
Study NCT03309059 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: zinc oxide
Description: Use of soap and water sanitation and application of zinc oxide.
Study NCT03309059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Irritant Barrier Film
Description: Use of soap and water hygiene and application of Non Irritant Barrier Film.
Study NCT01447472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: One single dose of MDMA ( 1.5 mg/kg; range: 75-100 mg)
Study NCT04294238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: The aerobic exercise intervention consisted of 12 weeks of aerobic exercise training of moderate intensity (about 75 percentage peak heart rate) of 40-60 min per time, 3-5 times per week, at least 150 min per week.
Study NCT02453191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Talimogene Laherparepvec
Study NCT02453191 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
Study NCT03412890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: Relugolix 40-mg tablet administered orally once daily
Study NCT03412890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol/norethindrone acetate
Description: Capsule containing co-formulated tablet of E2 (1 mg) and NETA (0.5 mg) administered orally once daily
Study NCT02172599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit-stand workstation provision
Description: The research compares the effects of a sit-stand workstation only and a multi-component sit-stand workstation intervention including individual and organisation-level approaches, with usual office-based working practice (no sit-stand workstation) over 12 months.
Study NCT04275414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Injection
Description: Bevacizumab 500mg + normal saline (NS) 100ml, ivdrip ≥90min
Study NCT02526394 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal vaccine
Description: Meningococcal vaccination
Study NCT02526394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertussis containing vaccine
Description: Pertussis containing vaccination
Study NCT00513864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextromethorphan
Description: one time dose - 0.3mg/kg PO
Study NCT00513864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine
Description: one time dose - 2mg/kg PO
Study NCT00513864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: one time dose - 0.15mg/kg IV
Study NCT03428555 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Care Pathway
Description: The intervention is a integrated care pathway based on the NICE Clinical Practice Guidelines and measurement-based care in the form of a flow chart. Each decision point on the pathway is guided by results of self-report measures for depression (the Mood and Feelings Questionnaire), functional impairment (Columbia Impairment Scales) and family functioning (the McMaster Family Assessment Device). The results of these scales and protocol recommendations are fed back to the patients, families and clinicians in order to make further treatment decisions
Study NCT03428555 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Treatment As Usual represents what clinicians would typically do when presented with an adolescent with depression. There is no algorithm provided to guide clinical decision-making and no systematic measurement-based care.
Study NCT00483509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: iv q3W 0.8 mcg/sqm NGR-hTNF
Study NCT00483509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: iv q3W 75 mg/sqm doxorubicin 60 minutes after NGR-hTNF infusion
Study NCT00185900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Preterm labor treatment with Magnesium Sulfate 4 gram bolus followed by 2 gm per hour infusion. 2 Gm bolus as needed and/or rate increase up to 4gm per hour were allowed at the discretion of the treating physician.
Study NCT00185900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Preterm labor treatment with Nifedipine 10 mg. sublingually every 20 minutes for three doses, followed by 20 mg. orally every 4 or 6 hours.
Study NCT02983942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ketogenic diet
Description: Ketogenic diet is given to maintain blood ketone level above 2 mmol/L.
Study NCT02983942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Routine diet
Description: Routine diet is given without blood ketone requirement
Study NCT02957123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal auto-M2-BFs
Description: Delivery is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.
Study NCT02965976 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Given IM
Study NCT02965976 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Undergo esophagectomy
Study NCT02965976 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: Undergo esophagectomy
Study NCT02965976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02965976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00305279 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary
Description: Dietary
Study NCT03342781 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high flow nasal oxygen therapy
Description: Oxygen therapy using a high-flow nasal cannula (HFNC) is a high-flow oxygen delivery system that enhances the efficiency of respiration by using high flow rates to clear dead space and provide fresh oxygen. This system supplies oxygen at a high flow rate through a loose nasal cannula.
Study NCT03342781 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diffuser oxygen mask
Description: diffuser mask is a low-flow delivery system, which is capable of delivering up to 90% of the fraction of inspired oxygen (FiO2) with low CO2 retention. In this system, the FiO2 can be adjusted by modifying the flow velocity to deliver the quantity of oxygen that the patient requires. Oxygen is supplied to the patient in a jet that flows from a device mounted on the oxygen mask. This ensures that a high concentration of oxygen is provided at a low flow rate.
Study NCT01890902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen 10% Cream
Study NCT01890902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00790829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transdermal nicotine patch
Description: Generic seven-milligram nicotine patches for 24hours, placebo patch for 24 hours
Study NCT04776941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Read positive messages
Study NCT04776941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Write about positive experiences
Study NCT04776941 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Write about neutral topics
Study NCT04776941 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Read neutral messages
Study NCT00085969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C - Exenatide 10 mcg once daily
Description: Subcutaneously injected, 10 mcg (0.04 mL), once daily
Study NCT00085969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide 20 mcg once daily
Description: Subcutaneously injected, 20 mcg (0.08 mL), once daily
Study NCT06365333 — intervention group
Intervention type: PROCEDURE
Intervention: Fluoroscopic-guided air-enema reduction (FGAR)
Description: A hand-held pump facilitated the delivery of atmospheric air, while pressure was monitored using a digital gauge. A two-way Foley's balloon catheter, ranging from 18oF to 24oF in diameter depending on age, was inserted rectally to introduce air. Following insertion, the balloon was filled with 10cc of saline to prevent air leakage, with patient immobilization ensured by leg straps and hand positioning above the head for abdominal exposure. Under intermittent fluoroscopy, the surgeon operated the pump with the right hand, inflating the catheter to 80 to 120 mmHg, simultaneously palpating the intussusceptum with the left hand, employing a deep gliding motion for deep and fixed cases. Successful reduction, indicated by air entry into the small bowel, was confirmed under fluoroscopy, with a subsequent brief rotating abdominal massage ensuring uniform air distribution throughout the small intestine, confirming complete reduction.
Study NCT04127136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-disciplinary obesity management therapy
Description: In twenty weeks, trainings by the physician, dietitian, psychologist and physiotherapist are conducted about medical information about obesity, using the technology to aid weight loss, what, when, how and why to eat, nutrition groups, ration management, water consumption, self-awareness, stress management, obesity and the association between the psychological processes, warming up and mobilization, correct stance and posture, and adequate physical activity. In addition to group meetings, in monthly individual meetings, the progress of the patients are evaluated.
Study NCT03525977 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fascia iliaca block arm
Description: The fascia iliaca block will be performed by the anesthesiologist on call
Study NCT03040583 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Patients data will be collected during their disease follow-up
Study NCT02545374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Study NCT02545374 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study NCT03050463 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood and saliva sample collection
Study NCT02137421 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol (3, 4´, 5 trihydroxystilbene)
Description: Resveratrol (RES) (3, 4´, 5 trihydroxystilbene)